Science
The Problem
Our ideas about disease outpace our ability to drug them. 80% of protein targets are currently untouched because they don’t fit conventional ideas about what proteins are amenable to small molecule medicines. For these proteins, it’s hard to find a chemical starting point, and for any protein it takes years of effort, a few dozen compounds at a time to turn those starting points into medicines.
Our Solution
We combine machine learning with massively parallel biochemical tools such as DNA Encoded Libraries (DELs) and Affinity Selected Mass Spectrometry (ASMS) to analyze more compounds more efficiently than ever before. By working with large datasets throughout our search process and letting our machine learning model guide our experiments, we are able to find molecules for the hardest problems in drug discovery, bringing first in class and best in class treatments to patients.
